JPS501B1 - - Google Patents
Info
- Publication number
- JPS501B1 JPS501B1 JP4271470A JP4271470A JPS501B1 JP S501 B1 JPS501 B1 JP S501B1 JP 4271470 A JP4271470 A JP 4271470A JP 4271470 A JP4271470 A JP 4271470A JP S501 B1 JPS501 B1 JP S501B1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4271470A JPS501B1 (de) | 1970-05-19 | 1970-05-19 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4271470A JPS501B1 (de) | 1970-05-19 | 1970-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS501B1 true JPS501B1 (de) | 1975-01-06 |
Family
ID=12643723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4271470A Pending JPS501B1 (de) | 1970-05-19 | 1970-05-19 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS501B1 (de) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232132A1 (en) | 2019-05-13 | 2020-11-19 | Emd Millipore Corporation | Synthetic self-replicating rna vectors encoding crispr proteins and uses thereof |
| WO2021050940A1 (en) | 2019-09-13 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles |
| WO2021055855A1 (en) | 2019-09-20 | 2021-03-25 | The Broad Institute, Inc. | Compositions and methods for delivering cargo to a target cell |
| EP3907286A1 (de) | 2016-06-02 | 2021-11-10 | Sigma-Aldrich Co., LLC | Verwendung von programmierbaren dna-bindenden proteinen zur verbesserung der gezielten genommodifizierung |
| WO2022056041A2 (en) | 2020-09-08 | 2022-03-17 | The Regents Of The University Of California | Rna and dna base editing via engineered adar |
| WO2022068912A1 (en) | 2020-09-30 | 2022-04-07 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
| WO2022120022A1 (en) | 2020-12-02 | 2022-06-09 | Regeneron Pharmaceuticals, Inc. | Crispr sam biosensor cell lines and methods of use thereof |
| EP4019636A1 (de) | 2011-12-21 | 2022-06-29 | Apse Llc | Verfahren unter verwendung von vlps mit gegenüber hydrolasen resistenten kapsiden |
| WO2022188797A1 (en) | 2021-03-09 | 2022-09-15 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
| WO2023077149A1 (en) | 2021-11-01 | 2023-05-04 | Sigma-Aldrich Co. Llc | Electroporation enhancers for crispr-cas systems |
| WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
-
1970
- 1970-05-19 JP JP4271470A patent/JPS501B1/ja active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4019636A1 (de) | 2011-12-21 | 2022-06-29 | Apse Llc | Verfahren unter verwendung von vlps mit gegenüber hydrolasen resistenten kapsiden |
| EP3907286A1 (de) | 2016-06-02 | 2021-11-10 | Sigma-Aldrich Co., LLC | Verwendung von programmierbaren dna-bindenden proteinen zur verbesserung der gezielten genommodifizierung |
| WO2020232132A1 (en) | 2019-05-13 | 2020-11-19 | Emd Millipore Corporation | Synthetic self-replicating rna vectors encoding crispr proteins and uses thereof |
| WO2021050940A1 (en) | 2019-09-13 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticles |
| WO2021055855A1 (en) | 2019-09-20 | 2021-03-25 | The Broad Institute, Inc. | Compositions and methods for delivering cargo to a target cell |
| WO2022056041A2 (en) | 2020-09-08 | 2022-03-17 | The Regents Of The University Of California | Rna and dna base editing via engineered adar |
| WO2022068912A1 (en) | 2020-09-30 | 2022-04-07 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
| WO2022120022A1 (en) | 2020-12-02 | 2022-06-09 | Regeneron Pharmaceuticals, Inc. | Crispr sam biosensor cell lines and methods of use thereof |
| WO2022188797A1 (en) | 2021-03-09 | 2022-09-15 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
| WO2023077149A1 (en) | 2021-11-01 | 2023-05-04 | Sigma-Aldrich Co. Llc | Electroporation enhancers for crispr-cas systems |
| WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |